(Q67927532)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

title

Systemic adjuvant therapy in women with resected node-negative breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Systemic Adjuvant Therapy in Women With Resected Node-Negative Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)61198-7

12 December 2022

4

J N Ingle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1

L C Hartmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

author name string

R. F. Marschke

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1861552

12 December 2022

D. J. Schaid

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1861552

12 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1861552

12 December 2022

publication date

1 August 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 September 2019

https://api.elsevier.com/content/article/PII:S0025619612611987?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)61198-7

https://api.elsevier.com/content/article/PII:S0025619612611987?httpAccept=text/plain

12 December 2022

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)61198-7

12 December 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

page(s)

805-813

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors

19 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

The Christie hospital adjuvant tamoxifen trial--status at 10 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Prognostic factors for recurrence and survival in axillary node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Indicators of prognosis in node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961198-7

Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer

7 January 2021

series ordinal

28

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)61198-7

12 December 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1861552%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1 reference